Abstract 5463: AMB304: A next generation ADC with topo I inhibitor, demonstrating robust preclinical efficacy against target overexpression tumors and high tolerability in non-human primate (NHP)
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Do-Hyun Nam, Yeong-Woo Kim, Byeongkwi Min, Wonsik Jung, Eunsuk Choi, Jungsu Shin, Nam-Gu Her
Institution: Samsung Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409632337